Fig. 1
From: A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer
Identification of novel tsRNA biomarkers from serum samples of PC patients. A Proportion of changed miRNAs and tsRNAs in serum from PC patients compared with normal controls. B The scatter plot figuratively expresses the changes in tsRNAs expression. C Hierarchical clustering indicates the differences in tsRNA expression profiling between two groups. D The six serum tsRNAs expression in PC patients in the training set. Serum samples from 24 PC patients and 24 controls were collected and subjected to qRT-PCR absolute quantification. E qRT-PCR shows the concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 in 150 PC patients and 100 control individuals enrolled in the validation set. F ROC curves of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 concentrations in serum samples from PC patients versus healthy controls. G Comparison of the diagnostic values of 2-tsRNA signature with CA19-9 and CEA in pancreatic cancer. H ROC analysis estimates the diagnostic value of 2-tsRNA signature in early stage pancreatic cancer. I qRT-PCR shows the serum concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 in other types of diseases [including 31 PC patients, 48 HCC patients, 60 breast cancer (BRC) patients, 53 non-small cell lung cancer patients (NSCLC), 23 hepatocirrhosis patients, 24 hepatitis patients and 48 control individuals]. **P < 0.01, ***P < 0.001, ****P < 0.0001